Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel Castera"'
Autor:
C. Dalban, F. Bonnetain, Jeremy Skrzypski, H. Taillia, Bruno Chauffert, Jean-Sébastien Guillamo, Daniel Castera, Didier Frappaz, Marc Frenay, L. Feuvret, Isabelle Tennevet, Jérôme Honnorat, Roland Schott, Luc Taillandier, Chantal Campello, Olivier Chinot, François Ghiringhelli, Michel Fabbro, Xavier Durando
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2014, 25 (7), pp.1442-1447. ⟨10.1093/annonc/mdu148⟩
Annals of Oncology, Elsevier, 2014, 25 (7), pp.1442-1447. ⟨10.1093/annonc/mdu148⟩
Background Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan (IRI) has been reported in recurrent disease. We evaluated BEV and IRI as neo-adjuvant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a206973777a5dffc6b1bf2f39f8c25
https://doi.org/10.1093/annonc/mdu148
https://doi.org/10.1093/annonc/mdu148
Autor:
Marc Frenay, Jérome Skrzypski, Michel Fabbro, Luc Taillandier, Bruno Chauffert, Chantal Campello, Brice Paquette, Roland Schott, Dewi Vernerey, Isabelle Tennevet, Loïc Feuvret, Sandrine Dabakuyo, Olivier Chinot, Daniel Castera, Franck Bonnetain, Amélie Anota, François Ghiringhelli, H. Taillia, Jean-Sébastien Guillamo, C. Dalban, Xavier Durando, François Ducray, Didier Frappaz
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2016, 5 (8), pp.1753-1764. ⟨10.1002/cam4.734⟩
Cancer Medicine, Wiley, 2016, 5 (8), pp.1753-1764. ⟨10.1002/cam4.734⟩
International audience; Glioblastoma is the most common malignant brain tumor in adults. Baseline health‐related quality of life (HRQoL) is a major subject of concern for these patients. We aimed to assess the independent prognostic value of HRQoL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a67bb49a8755befd5e3700d8d9707a5
https://hal.archives-ouvertes.fr/hal-03036055
https://hal.archives-ouvertes.fr/hal-03036055
Autor:
Franck Bonnetain, Jeremy Skrzypski, Isabelle Tennevet, Tienhan Sandrine Dabakuyo, Roland Schott, Michel Fabbro, Astrid Pozet, Olivier Chinot, Daniel Castera, Bruno Chauffert, Amélie Anota, François Ghiringhelli, H. Taillia, Loïc Feuvret, Marc Frenay, Didier Frappaz, Cécile Dalban, Jérôme Honnorat, Luc Taillandier, Chantal Campello
Publikováno v:
Journal of Clinical Oncology. 33:2018-2018
2018 Background: Two clinical trials investigating the addition of bevacizumab (BEV) to TMZ treatment (Chinot et al., NEJM 2014; Gilbert et al., NEJM 2014) for unresectable glioblastoma (GB) highli...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::019a667c70f480ab94b65a75bcff7cb5
https://doi.org/10.1200/jco.2015.33.15_suppl.2018
https://doi.org/10.1200/jco.2015.33.15_suppl.2018
Autor:
Bruno Chauffert, O. L. Chinot, Luc Taillandier, Chantal Campello, F. Ghiringhelli, Jérôme Honnorat, Didier Frappaz, Jeremy Skrzypski, Marc Frenay, H. Taillia, F. Bonnetain, Rémy Guillevin, Tienhan Sandrine Dabakuyo, Jean-Sébastien Guillamo, Isabelle Tennevet, Xavier Durando, Daniel Castera, Loïc Feuvret, Michel Fabbro, Roland Schott
Publikováno v:
Journal of Clinical Oncology. 29:2029-2029
2029^ Background: The prognosis of unresectable glioblastoma (GBM) remains poor despite temozolomide- based chemoradiation with a median of 6 month progression-free survival (PFS). Activity of bevacizumab/irinotecan has been reported in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1750dc45c154829ac67ce9bd6e140a45
https://doi.org/10.1200/jco.2011.29.15_suppl.2029
https://doi.org/10.1200/jco.2011.29.15_suppl.2029